Brutons Tyrosine Kinase Btk Inhibitors Competitive Landscape Pipeline And Market Analysis

Overview

Bruton's tyrosine kinase (Bruton’s agammaglobulinemia tyrosine kinase; BTK) is a cytoplasmic tyrosine kinase which is important in B-lymphocyte development, differentiation, and signaling. It is a member of the Tec family of kinases which is involved in regulating the B cell proliferation. Bruton's tyrosine kinase is also known as tyrosine-protein kinase. According to study conducted by F. Dammeijer et al., Bruton’s tyrosine kinase (BTK) plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK is expressed throughout B cell development. It sustains the developmental program of pre-B cells by limiting the pre-B cell expansion and by promoting B-cell differentiation.


“Bruton's Tyrosine Kinase (BTK) Inhibitors – Competitive Landscape, Market and Pipeline Analysis, 2020” report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Bruton's Tyrosine Kinase (BTK) Inhibitors, including the marketed and pipeline products in this space. This report provides detailed information on marketed products with historical and forecasted sales till 2030. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, licensing, deals, and other development activities is also involved in this report Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the understanding of the unmet needs, market drivers and barriers of the Bruton’s Tyrosine Kinase Inhibitors market.


Future competitive landscape of Bruton's Tyrosine Kinase (BTK) Inhibitors is estimated to be very strong. Key emerging drugs including Principia Biopharma’ PNR-1008 and others are going to be Blockbuster in the upcoming years.


Delveinsight report on Bruton's Tyrosine Kinase (BTK) Inhibitors help companies in understanding market dynamics based on this mechanism of action and therefore giving opportunities for a strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition, reports will assuage companies to detect conditions, determine genetic predisposition and biological response to Bruton’s Tyrosine Kinase (BTK) Inhibitors.

Bruton's Tyrosine Kinase (BTK) Inhibitors Report Key Features

The report provides insights into:

  • Detailed market drug profiles available in the market indicated for this mechanism of action with historical and forecasted sales till 2030.
  • A number of companies developing therapies of Bruton’s Tyrosine Kinase (BTK) Inhibitors with aggregate therapies developed by each company for the same.
  • Detailed profiles of therapeutic candidates in nonclinical stage, early-stage, mid-stage and late-stage of development for Bruton’s Tyrosine Kinase (BTK) Inhibitors.
  • Analyses key players involved in Bruton’s Tyrosine Kinase (BTK) Inhibitors targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Active pipeline therapies assessment under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detail analysis of collaboration (company–company collaborations and company–academia collaborations), licensing agreement and financing details for future developments of Bruton’s Tyrosine Kinase (BTK) Inhibitors.


The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.

Bruton's Tyrosine Kinase (BTK) Inhibitors Analytical Perspective by DelveInsight

  • In-depth Bruton's Tyrosine Kinase (BTK) Inhibitors Analysis: Assessment of Products

This report provides an in-depth commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, agreements, licensing, and acquisition – deal value trends. The sub-segmentation is described in the report which provides company–company collaborations (licensing/partnering), company–academia collaborations, and acquisition analysis in both graphical and tabulated form.


  • Bruton's Tyrosine Kinase (BTK) Inhibitors Clinical Assessment of Products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this mechanism of action.

Scope of the Report

  • The Bruton’s Tyrosine Kinase Inhibitors report provides an overview of this mechanism of action, role, significance, pathway, types, and clinical application of IDH inhibitors.
  • Therapeutic Assessment: Therapeutic pipeline activity and assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of therapeutic products for Bruton’s Tyrosine Kinase (BTK) Inhibitors with key coverage of developmental activities, including collaborations, agreements, licensing, mergers and acquisition, funding, designations, technology and other product-related details.
  • In-depth Bruton’s Tyrosine Kinase Inhibitors research and development progress and trial details results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Bruton’s Tyrosine Kinase (BTK) Inhibitors.
  • The report has also covered the worldwide market of Bruton’s Tyrosine Kinase (BTK) Inhibitors, information of marketed therapies, their historical and forecasted sales till 2030.
  • It also includes patent expiry details impact on market after expiry.
  • Key topics covered include strategic competitor assessment, market characterization, opportunities, unmet needs, market growth factors, barriers and challenges along with SWOT analysis of the Bruton’s Tyrosine Kinase Inhibitors market.
  • Analysis of the current and future market competition in the global Bruton’s Tyrosine Kinase Inhibitors market. Current scenario of the market with upcoming blockbuster molecules and their impact on the overall market.

Report Highlights

  • In the coming years, the Bruton’s Tyrosine Kinase Inhibitors market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bruton’s Tyrosine Kinase Inhibitors R&D. The Bruton’s Tyrosine Kinase Inhibitors therapies under development are focused on novel approaches to treat/improve the disease condition.  
  • There are many companies involved in developing therapies for Bruton’s Tyrosine Kinase (BTK) Inhibitors. Launch of emerging therapies of Bruton’s Tyrosine Kinase (BTK) Inhibitors will significantly impact the market.
  • A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Bruton’s Tyrosine Kinase (BTK) Inhibitors.   
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late-stage of development for the treatment of Bruton’s Tyrosine Kinase (BTK) Inhibitors includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
  • The report provides the detailed analysis of 30+ products along with 25+ companies involved.

Companies Mentioned

  • BeiGene
  • Merck
  • Principia Biopharma
  • ACEA Biosciences
  • Bristol- Myers Squibb
  • AbbVie
  • Celgene Corporation
  • Ono Pharmaceutical
  • Roche
  • Novartis

And many more …

Key Questions

  • What are Bruton’s Tyrosine Kinase (BTK) Inhibitors, their role and significance in the treatment of disease conditions?
  • What are the current treatment options based on the Bruton’s Tyrosine Kinase (BTK) Inhibitors available in the market?
  • How the historical and forecasted sales of the marketed therapies determine their scenario in the current Bruton’s Tyrosine Kinase Inhibitors market?
  • How many therapies are developed by each company for Bruton’s Tyrosine Kinase (BTK) Inhibitors to treat disease conditions?
  • What are the key collaborations (Industry–Industry, Industry–Academia), mergers and acquisitions, licensing activities related to the Bruton’s Tyrosine Kinase Inhibitors therapies?
  • Which are the dormant and discontinued products and the reasons for dormancy and discontinuation?
  • What is the unmet need for current therapies developed on the basis of this mechanism of action?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bruton’s Tyrosine Kinase (BTK) Inhibitors and their status?

 

1. Report Introduction

2. Bruton's Tyrosine Kinase (BTK) Inhibitors

2.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors Overview

2.2. Bruton’s Tyrosine Kinase (BTK) Inhibitors Types

2.3. Bruton’s Tyrosine Kinase (BTK) Inhibitors Structure

2.4. Bruton’s Tyrosine Kinase (BTK) Inhibitors Mechanism of Action

2.5. Bruton’s Tyrosine Kinase (BTK) Inhibitors Application

3. Competitive Landscape

3.1. Marketed Product Profiles

3.1.1. Imbruvica: Janssen

3.1.1.1. Product Description

3.1.1.2. Research and Development

3.1.1.2.1. Clinical Studies

3.1.1.3. Other Pipeline Activities

3.1.1.4. Product Development Activities

3.1.1.5. Idhifa Sales

4. Bruton’s Tyrosine Kinase (BTK) Inhibitors - DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors Companies Collaborations, Licensing, Acquisition – Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Bruton’s Tyrosine Kinase (BTK) Inhibitors Collaboration Deals

4.1.2.1. Company–Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Company–University Collaborations (Licensing/Partnering) Analysis

4.1.2.3. Bruton’s Tyrosine Kinase (BTK) Inhibitors Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Stage of Development

5.1.2. Assessment by Product Type (Mono/Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Pipeline Therapeutics

6.1. Comparative Analysis

7. Late-Stage Products (Phase-III)

8. Mid-Stage Products (Phase-II)

9. Early-Stage Products (Phase-I)

10. Preclinical and Discovery Stage Products

11. Bruton’s Tyrosine Kinase (BTK) Inhibitors Emerging Drug Profiles

11.1. PRN-1008: Principia Biopharma

11.1.1. Product Description

11.1.2. Research and Development

11.1.2.1. Clinical Studies

11.1.3. Product Development Activities

11.1.4. Tabulated Product Summary

11.1.4.1. General Description Table

Many more drugs with detailed profiles provided in the report …

12. Bruton’s Tyrosine Kinase (BTK) Inhibitors Key Companies

13. Bruton’s Tyrosine Kinase (BTK) Inhibitors Key Products

14. Inactive Products

14.1. Dormant Products

14.1.1. Reason for Dormancy

14.2. Discontinued Products

14.2.1. Reason for Discontinuation

15. Bruton’s Tyrosine Kinase (BTK) Inhibitors - Unmet Needs

16. Bruton’s Tyrosine Kinase (BTK) Inhibitors – Market Drivers and Barriers

17. Bruton’s Tyrosine Kinase (BTK) Inhibitors - Future Perspectives and Conclusion

18. Bruton’s Tyrosine Kinase (BTK) Inhibitors Analyst Views

19. Appendix

20. Report Methodology

20.1. Secondary Research

20.2. Expert Panel Validation 

List of Table

Table 1 Assessment Summary

Table 2 Company-Company Collaborations (Licensing/Partnering) Analysis

Table 3 Bruton’s Tyrosine Kinase (BTK) Inhibitors Acquisition Analysis

Table 4 Assessment by Phase of Development

Table 5 Assessment by Product Type (Mono/Combination)

Table 6 Assessment by Stage and Product Type

Table 7 Assessment by Route of Administration

Table 8 Assessment by Stage and Route of Administration

Table 9 Assessment by Molecule Type

Table 10 Assessment by Stage and Molecule Type

Table 11 Assessment by MOA

Table 12 Assessment by Stage and MOA

Table 13 Assessment by Target

Table 14 Assessment by Stage and Target

Table 15 Late-Stage Products (Phase-III)

Table 16 Mid-Stage Products (Phase-II)

Table 17 Early-Stage Products (Phase-I)

Table 18 Preclinical and Discovery Stage Products

Table 19 Inactive Products

Table 20 Dormant Products

Table 21 Discontinued Products 

List of Figures

Figure 1 Bruton’s Tyrosine Kinase (BTK) Inhibitors Structure

Figure 2 Bruton’s Tyrosine Kinase (BTK) Inhibitors Mechanism

Figure 3 Bruton’s Tyrosine Kinase (BTK) Inhibitors Types

Figure 4 Bruton’s Tyrosine Kinase (BTK) Inhibitors Clinical Significance

Figure 5 Bruton’s Tyrosine Kinase (BTK) Inhibitors companies collaborations, Licensing, Acquisition – Deal Value Trends

Figure 6 Company–Company Collaborations (Licensing/Partnering) Analysis

Figure 7 Bruton’s Tyrosine Kinase (BTK) Inhibitors Acquisition Analysis

Figure 8 Assessment by Phase of Development

Figure 9 Assessment by Product Type (Mono/Combination)

Figure 10 Assessment by Stage and Product Type

Figure 11 Assessment by Route of Administration

Figure 12 Assessment by Stage and Route of Administration

Figure 13 Assessment by Molecule Type

Figure 14 Assessment by Stage and Molecule Type

Figure 15 Assessment by MOA

Figure 16 Assessment by Stage and MOA

Figure 17 Late-Stage Products (Phase-III)

Figure 18 Mid-Stage Products (Phase-II)

Figure 19 Early-Stage Products (Phase-I)

Figure 20 Preclinical and Discovery Stage Products

Figure 21 Inactive Products

Figure 22 Dormant Products

Figure 23 Discontinued Products

Figure 24 Unmet Needs

Figure 25 Market Drivers and Barriers

• BeiGene

• Merck

• Principia Biopharma

• ACEA Biosciences

• Bristol- Myers Squibb

• AbbVie

• Celgene Corporation

• Ono Pharmaceutical

• Roche

• Novartis

  • Tags:
  • Bruton's Tyrosine Kinase (BTK) Inh...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Bruton's Tyrosine Kinase (BTK) Inhi...

Forward to Friend

Need A Quote